CO2021002230A2 - Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas - Google Patents
Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadasInfo
- Publication number
- CO2021002230A2 CO2021002230A2 CONC2021/0002230A CO2021002230A CO2021002230A2 CO 2021002230 A2 CO2021002230 A2 CO 2021002230A2 CO 2021002230 A CO2021002230 A CO 2021002230A CO 2021002230 A2 CO2021002230 A2 CO 2021002230A2
- Authority
- CO
- Colombia
- Prior art keywords
- treatment
- ehgna
- ehna
- combinations
- related diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Abstract
Se describe en la presente la combinación de (S)-2-(5-((3-etoxi-piridin-2-il)oxi)piridin-3-il)-N-(tetrahidrofuran-3-il)pirimidina-5-carboxamida, o una sal farmacéuticamente aceptable de la misma, y ácido 4-(4-(1-isopropil-7-oxo-1,4,6,7-tetrahidrospiro-[indazol-5,4’-piperidina]-1’-carbonil)-6-metoxipiridin-2-il)benzoico, o sal farmacéuticamente aceptable del mismo, para tratamiento de enfermedades, incluyendo esteatohepatitis no alcohólica (EHNA), en mamíferos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862726172P | 2018-08-31 | 2018-08-31 | |
US201962883860P | 2019-08-07 | 2019-08-07 | |
PCT/IB2019/057259 WO2020044266A1 (en) | 2018-08-31 | 2019-08-28 | Combinations for treatment of nash/nafld and related diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021002230A2 true CO2021002230A2 (es) | 2021-03-08 |
Family
ID=68165623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0002230A CO2021002230A2 (es) | 2018-08-31 | 2021-02-23 | Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas |
Country Status (22)
Country | Link |
---|---|
US (2) | US11254660B2 (es) |
EP (1) | EP3843740A1 (es) |
JP (1) | JP7161605B2 (es) |
KR (1) | KR102614808B1 (es) |
CN (1) | CN112955147A (es) |
AU (1) | AU2019329884B2 (es) |
BR (1) | BR112021003039A2 (es) |
CA (1) | CA3110601C (es) |
CL (1) | CL2021000491A1 (es) |
CO (1) | CO2021002230A2 (es) |
CR (1) | CR20210110A (es) |
DO (1) | DOP2021000036A (es) |
EC (1) | ECSP21012501A (es) |
IL (1) | IL281093A (es) |
MA (1) | MA53496A (es) |
MX (1) | MX2021002428A (es) |
PH (1) | PH12021550339A1 (es) |
SG (1) | SG11202101503RA (es) |
TW (1) | TWI718644B (es) |
UY (1) | UY38351A (es) |
WO (1) | WO2020044266A1 (es) |
ZA (1) | ZA202101090B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11590161B2 (en) * | 2018-08-13 | 2023-02-28 | Viscera Labs, Inc. | Therapeutic composition and methods |
AU2019382642A1 (en) * | 2018-11-22 | 2021-06-10 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
JP2021134211A (ja) * | 2020-02-24 | 2021-09-13 | ファイザー・インク | Nafld/nashおよび関連疾患の処置のための組合せ |
JP2022058085A (ja) * | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ |
BR112022017963A2 (pt) * | 2020-03-11 | 2022-10-18 | Dong A St Co Ltd | Composição farmacêutica para prevenção ou tratamento de esteato-hepatite não alcoólica |
WO2021211959A2 (en) * | 2020-04-18 | 2021-10-21 | Inipharm, Inc. | Methods and compositions for treating drug induced steatohepatitis |
US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
CN113816948B (zh) * | 2020-06-19 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
PE20231206A1 (es) * | 2020-08-21 | 2023-08-17 | Terns Pharmaceuticals Inc | Compuestos como agonistas de glp-1r |
CN112635049A (zh) * | 2020-12-23 | 2021-04-09 | 无锡市第二人民医院 | 一种研究HSD17B13 rs72613567基因变异和肾功能损伤之间关系的方法 |
WO2023169456A1 (en) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
DE3065190D1 (en) | 1979-11-05 | 1983-11-10 | Beecham Group Plc | Enzyme derivatives, and their preparation |
DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
AU1537292A (en) | 1991-04-16 | 1992-11-17 | Nippon Shinyaku Co. Ltd. | Method of manufacturing solid dispersion |
US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
DK0901786T3 (da) | 1997-08-11 | 2007-10-08 | Pfizer Prod Inc | Faste farmaceutiske dispersioner med foröget biotilgængelighed |
SK18822000A3 (sk) | 1998-07-06 | 2001-12-03 | Bristol-Myers Squibb Company | Bifenylsulfónamidy ako duálne antagonisty angiotenzínového a endotelínového receptora |
MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
DE60219295T2 (de) | 2001-02-28 | 2008-01-03 | Merck & Co., Inc. | Acylierte piperidinderivate als melanocortin-4-rezeptoragonisten |
ATE303178T1 (de) | 2002-02-27 | 2005-09-15 | Pfizer Prod Inc | Acc-hemmer |
GEP20084421B (en) | 2004-05-12 | 2008-07-10 | Pfizer Prod Inc | Proline derivatives and their use as dipeptidyl peptidase iv inhibitors |
CN1950374A (zh) | 2004-05-25 | 2007-04-18 | 辉瑞产品公司 | 四氮杂苯并[e]甘菊环衍生物及其类似物 |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
NL2000581C2 (nl) | 2006-04-20 | 2008-01-03 | Pfizer Prod Inc | Aangecondenseerde fenylamidoheterocyclische verbindingen. |
CN101541809A (zh) | 2006-11-29 | 2009-09-23 | 辉瑞产品公司 | 螺环酮乙酰基-CoA羧化酶抑制剂 |
US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
EP2297164A1 (en) | 2008-05-28 | 2011-03-23 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
JP5435592B2 (ja) | 2008-05-28 | 2014-03-05 | ファイザー・インク | ピラゾロスピロケトンアセチルCoAカルボキシラーゼ阻害剤 |
JP2011529483A (ja) | 2008-07-29 | 2011-12-08 | ファイザー・インク | フッ素化ヘテロアリール |
GEP20135803B (en) | 2008-08-28 | 2013-04-10 | Pfizer | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives |
TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
DK2406253T3 (da) | 2009-03-11 | 2013-08-12 | Pfizer | Benzofuranylderivater anvendt som glucokinase-inhibitorer |
CA2754685A1 (en) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Substituted indazole amides |
JP2012520868A (ja) | 2009-03-20 | 2012-09-10 | ファイザー・インク | 3−オキサ−7−アザビシクロ[3.3.1]ノナン |
JP2012526096A (ja) | 2009-05-08 | 2012-10-25 | ファイザー・インク | Gpr119調節因子 |
JP2012526097A (ja) | 2009-05-08 | 2012-10-25 | ファイザー・インク | Gpr119調節因子 |
WO2010140092A1 (en) | 2009-06-05 | 2010-12-09 | Pfizer Inc. | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
CH702192A1 (de) | 2009-11-04 | 2011-05-13 | New Dent Ag | Keramisches Implantat. |
PL2621493T3 (pl) | 2010-09-30 | 2017-01-31 | Pfizer Inc. | N1-pirazolospiroketonowe inhibitory karboksylazy acetylo-CoA |
CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
MX2017008844A (es) | 2015-01-09 | 2018-03-14 | Gilead Apollo Llc | Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico. |
SI3397631T1 (sl) | 2015-12-29 | 2022-01-31 | Pfizer Inc. | Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze |
AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
CN106271089B (zh) | 2016-09-30 | 2019-01-25 | 英诺激光科技股份有限公司 | 一种激光薄膜刻蚀装置及方法 |
MA56480B1 (fr) | 2016-12-16 | 2022-12-30 | Pfizer | Agonistes du récepteur glp-1 et leurs utilisations |
SG11202003600QA (en) | 2017-11-21 | 2020-06-29 | Pfizer | Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid |
-
2019
- 2019-08-28 US US16/553,818 patent/US11254660B2/en active Active
- 2019-08-28 CR CR20210110A patent/CR20210110A/es unknown
- 2019-08-28 CA CA3110601A patent/CA3110601C/en active Active
- 2019-08-28 SG SG11202101503RA patent/SG11202101503RA/en unknown
- 2019-08-28 EP EP19783644.8A patent/EP3843740A1/en active Pending
- 2019-08-28 MX MX2021002428A patent/MX2021002428A/es unknown
- 2019-08-28 WO PCT/IB2019/057259 patent/WO2020044266A1/en active Application Filing
- 2019-08-28 CN CN201980071389.XA patent/CN112955147A/zh active Pending
- 2019-08-28 JP JP2021510174A patent/JP7161605B2/ja active Active
- 2019-08-28 AU AU2019329884A patent/AU2019329884B2/en active Active
- 2019-08-28 KR KR1020217009415A patent/KR102614808B1/ko active IP Right Grant
- 2019-08-28 BR BR112021003039-5A patent/BR112021003039A2/pt unknown
- 2019-08-28 TW TW108130771A patent/TWI718644B/zh active
- 2019-08-28 MA MA053496A patent/MA53496A/fr unknown
- 2019-08-29 UY UY0001038351A patent/UY38351A/es unknown
-
2021
- 2021-02-17 PH PH12021550339A patent/PH12021550339A1/en unknown
- 2021-02-17 ZA ZA2021/01090A patent/ZA202101090B/en unknown
- 2021-02-23 CO CONC2021/0002230A patent/CO2021002230A2/es unknown
- 2021-02-23 EC ECSENADI202112501A patent/ECSP21012501A/es unknown
- 2021-02-24 IL IL281093A patent/IL281093A/en unknown
- 2021-02-25 DO DO2021000036A patent/DOP2021000036A/es unknown
- 2021-02-26 CL CL2021000491A patent/CL2021000491A1/es unknown
- 2021-10-11 US US17/498,256 patent/US20220023299A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3843740A1 (en) | 2021-07-07 |
KR102614808B1 (ko) | 2023-12-19 |
CR20210110A (es) | 2021-05-13 |
KR20210053929A (ko) | 2021-05-12 |
MA53496A (fr) | 2021-12-08 |
SG11202101503RA (en) | 2021-03-30 |
US20200071306A1 (en) | 2020-03-05 |
AU2019329884B2 (en) | 2022-01-27 |
US20220023299A1 (en) | 2022-01-27 |
CA3110601A1 (en) | 2020-03-05 |
UY38351A (es) | 2020-03-31 |
JP7161605B2 (ja) | 2022-10-26 |
US11254660B2 (en) | 2022-02-22 |
DOP2021000036A (es) | 2021-04-15 |
TW202026292A (zh) | 2020-07-16 |
IL281093A (en) | 2021-04-29 |
CL2021000491A1 (es) | 2021-08-20 |
CN112955147A (zh) | 2021-06-11 |
PH12021550339A1 (en) | 2021-10-04 |
CA3110601C (en) | 2023-09-05 |
BR112021003039A2 (pt) | 2021-05-18 |
JP2021535126A (ja) | 2021-12-16 |
TWI718644B (zh) | 2021-02-11 |
MX2021002428A (es) | 2023-01-02 |
WO2020044266A1 (en) | 2020-03-05 |
ZA202101090B (en) | 2022-06-29 |
AU2019329884A1 (en) | 2021-03-11 |
ECSP21012501A (es) | 2021-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021000491A1 (es) | Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas | |
CO2020001860A2 (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos | |
MX2016014634A (es) | Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
RU2014120792A (ru) | Способ лечения стромальных опухолей желудочно-кишечного тракта | |
RU2017105353A (ru) | Соединения | |
BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
EA201791199A1 (ru) | Способ лечения болезни альцгеймера | |
UY29964A1 (es) | Formas de cristal f,g,h,i, y k del mesilato de imatinib | |
BR112015030578A2 (pt) | combinações farmacêuticas | |
AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
AR112284A1 (es) | Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico | |
BR112014004587A2 (pt) | combinações sinérgicas de inibidores de pi3k- e de mek | |
BRPI0921692A2 (pt) | composto carbamato ou o sal do mesmo | |
PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
AR117614A1 (es) | Forma de dosificación farmacéutica administrable por vía oral con liberación modificada | |
PH12021550218A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
RU2019111873A (ru) | Новые антимикробные соединения, их применение для лечения инфекций млекопитающих и новый метаболический механизм | |
AR065477A1 (es) | Diaminopirimidinas | |
AR103118A1 (es) | Tratamientos médicos basados en anamorelina | |
CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
NZ708802A (en) | Pharmaceutical combinations comprising a protein kinase c inhibitor compound and a mitogen activated protein kinase inhibitor compound | |
MA39448B1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
RU2017124612A (ru) | Комбинация производного 6-оксо-1, 6-дигидро-пиридазона, обладающего противораковой активностью, с ингибитором рэфр |